- Home
- HYPR vs MAIA Comparison
HYPR vs MAIA Comparison
Compare HYPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | MAIA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HYPR | MAIA |
|---|---|---|
| Price | $1.03 | $1.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.28 | N/A |
| AVG Volume (30 Days) | ★ 625.1K | 449.7K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $35.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.87 |
| 52 Week High | $2.22 | $2.74 |
Technical Indicators
Market Signals| Indicator | HYPR | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 55.91 |
| Support Level | $0.85 | $1.07 |
| Resistance Level | $1.10 | $1.25 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 64.18 | 61.02 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.